DOI: 10.1055/s-00000030

Der Klinikarzt

References

Tewari KS. et al.
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

The Lancet 2017;
390 (10103) 1654-1663

Download Bibliographical Data

Search in:
Access:
Access: